Metabolic therapy as a comprehensive approach to the treatment and prevention of cardiovascular diseases | Ukrainian Medical Journal

The article analyzes the possibilities of the impact of metabolic therapy, namely the Cardonat Max complex, on improving energy exchange in the myocardium, reducing the development of cardiac dysfunction, symptoms of ischemia, and improving indicators of lipid metabolism in the body. It has been established that the use of Cardonat Max in addition to standard therapy in patients with diseases of the cardiovascular system leads to an increase in the viability and functional activity of the myocardium and an improvement in the energy support of the activity of adaptation systems

References

1. Bing R.J., Siegel A.L., Vitale A. et al. (1953) Metabolic studies on the human heart in vivo. I. Studies on carbohydrate metabolism of the human heart. Am. J. Med., 15: 284–296.
2. Bing R.J., Siegel A., Ungar I. et al. (1954) Metabolism of the human heart: II. Studies on fat, ketone and amino acid metabolism. Am. J. Med., 16: 504–515.
3. Rehman I., Nassereddin A., Rehman A. (2023) StatPearls. StatPearls Publishing; Treasure Island (FL). Anatomy, Thorax, Pericardium.
4. Thompson B.R., Metzger J.M. (2014) Cell biology of sarcomeric protein engineering: disease modeling and therapeutic potential. Anat. Rec. (Hoboken), 297(9): 1663–1669.
5. Lopaschuk G.D., Ussher J.R., Folmes C.D. et al. (2010) Myocardial fatty acid metabolism in health and disease. Physiol. Rev., 90: 207–258.
6. Patel D.M., Green K.J. (2014) Desmosomes in the heart: a review of clinical and mechanistic analyses. Cell Commun. Adhes., 21(3): 109–128.Wang H. , Xia B., Lin M. et al. (2020) Succinic acid inhibits the activity of cytochrome P450 (CYP450) enzymes. Pharm. Biol., 58(1): 1159–1164.
7. Attali V., Parnes M., Ariav Y. et al. (2006) Regulation of insuline secretion and proinsulin biosynthesis by succinate. Endocrinology, 147(11): 5110–5118.
8. Лабенська І.Б. (2016) Бурштинова кислота — потенційний фармакофор при моделюванні нових біорегуляторів на основі азотовмісних гетероциклів. НПВ «Фармакологія та лікарська токсикологія», 2(48): 3–13.
9. Shah A.K., Dhalla N.S. (2021) Effectiveness of Some Vitamins in the Prevention of Cardiovascular Disease: A Narrative Review. Front. Physiol., 12: 729255.
10. Kobulia B., Chapichadze Z., Andriadze G., Machavariani P. (2002) Effects of carnitine on 6-month incidence of mortality and heart failure in patients with acute myocardial infarction. Ann. Biomed. Res. Educ., 2(3): 240–243.
11. Retter A.S. (1999) Carnitine and its role in cardiovascular disease. Heart Dis., 1(2): 108–113.
12. Eknoyan G., Latos D.L., Lindberg J. (2003) Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am. J. Kidney Dis., 41: 868–876.
13. Pekala J., Patkowska-Sokola B., Bodkowski R. et al. (2011) L-carnitine — metabolic functions and meaning in humans life. Curr. Drug Metab., 12: 667–678.
14. http://www.prisma-statement.org/.